LAVA Therapeutics

Yahoo Finance • last year

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody® platfo... Full story

Yahoo Finance • last year

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engage... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfoli... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V. (Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engag... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

• LAVA-1207 for the treatment of prostate cancer will continue as the lead program • LAVA-051 Phase 1/2a clinical trial will be discontinued • Associated cost savings and initiatives are expected to extend the cash runway further into 2026... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multip... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-d... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicitiesPreliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-de... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engag... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engager... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces Appointment of New Directors to the Board

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-d... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

UTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec. 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gam... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPrese... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story

Yahoo Finance • 2 years ago

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma d... Full story

Yahoo Finance • 3 years ago

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story

Yahoo Finance • 3 years ago

LAVA Therapeutics Announces Two Appointments to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, June 15, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma de... Full story